Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 282, Issue , 2015, Pages 39-44

  Serrano Pertierra, Esther ^a   Blanco Gelaz, Miguel A ^a,e   Oliva Nacarino, Pedro ^a   Martínez Camblor, Pablo ^b,d   Villafani, Javier ^a   López Larrea, Carlos ^a,c   Cernuda Morollón, Eva ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Oficina de Investigación Sanitaria   (Spain)

^c Section of Nephrology   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^e HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Chemotaxis; CXCL12; CXCR4; Multiple sclerosis; NK

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1; CXCR4 PROTEIN, HUMAN; CYTOKINE;

ADULT; ARTICLE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CHEMOTAXIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY DISEASE; LEUKOCYTE; LYMPHOCYTE MIGRATION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; RELAPSE; REMISSION; ANALYSIS OF VARIANCE; DRUG EFFECTS; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; CENTRAL NERVOUS SYSTEM; CHEMOKINE CXCL12; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, CXCR4; YOUNG ADULT;

EID: 84928559720     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.03.007     Document Type: Article

References (30)

1. Airas L., Saraste M., Rinta S., Elovaara I., Huang Y.H., Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. 2008, 151:235-243. Finnish Multiple Sclerosis and Pregnancy Study Group.
2. Baumgarth N., Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J. Immunol. Methods 2000, 243:77-97.
3. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
4. Calderón T.M., Eugenin E.A., López L., Kumar S.S., Hesselgesser J., Raine C.S., Berman J.W. A role for CXCL12 (SDF-1a) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J. Neuroimmunol. 2006, 177:27-39.
5. Dressel A., Mirowska-Guzel D., Gerlach C., Weber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-β1a. Acta Neurol. Scand. 2007, 116:164-168.
6. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J. Neural Transm. 2006, 113:477-485.
7. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
8. Huang D., Shi F.D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., He T.T., Weaver J.T., Ljunggren H.G., Biron C.A., Littman D.R., Ransohoff R.M. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006, 20:896-905.
9. Kastrukoff L.F., Lau A., Wee R., Zecchini D., White R., Paty D.W. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J. Neuroimmunol. 2003, 145:103-104.
10. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisa P., Ransohoff R.M., Hofbauer M., Farina C., Derfuss T., Hartle C., Newcombe J., Hohlfeld R., Meinl E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211.
11. Li M., Ransohoff R.M. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog. Neurobiol. 2008, 84:116-131.
12. López C., Comabella M., Tintoré M., Sastre-Garriga J., Montalban X. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. Mult. Scler. 2006, 12:421-427.
13. Lünemann J.D., Münz C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis?. Brain 2008, 131:1681-1683.
14. Martínez-Cáceres E.M., Espejo C., Brieva L., Pericot I., Tintoré M., Sáez-Torres I., Montalban X. Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Mult. Scler. 2002, 8:390-395.
15. Martínez-Rodríguez J.E., López-Botet M., Munteis E., Rio J., Roquer J., Montalban X., Comabella M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol. 2011, 141:348-356.
16. Matsumoto Y., Kohyama K., Aikawa Y., Shin T., Kawazoe Y., Suzuki Y., Tanuma N. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 1998, 28:1681-1688.
17. McCandless E.E., Piccio L., Woerner B.M., Schmidt R.E., Rubin J.B., Cross A.H., Klein R.S. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 2008, 172:799-808.
18. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9:540-549.
19. Moll N.M., Cossoy M.B., Fisher E., Staugaitis S.M., Tucky B.H., Chang A., Rietsch A.M., Fox R.J., Trapp B.D., Ransohoff R.M. Imaging correlates of leukocyte accumulation and CXCR4/CXCR12 in multiple sclerosis. Arch. Neurol. 2009, 66:44-53.
20. Morandi B., Bramanti P., Bonaccorsi I., Montalto E., Oliveri D., Pezzino G., Navarra M., Ferlazzo G. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol. Res. 2008, 57:1-5.
21. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W., Investigators A.F.F.I.R.M. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
22. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
23. Prat A., Al-Asmi A., Duquette P., Antel J.P. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann. Neurol. 1999, 46:253-256.
24. Prat A., Biernacki K., Lavoie J., Poirier J., Duquette P., Antel J.P. Migration of multiple sclerosis lymphocytes through brain endothelium. Arch. Neurol. 2002, 59:391-397.
25. Rodríguez-Martín E., Picón C., Costa-Frossard L., Alenda R., Sainz de la Maza S., Roldán E., Espiñol M., Villar L.M., Álvarez-Cermeño J.C. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin. Exp. Immunol. 2015, 10.1111/cei.12580.
26. Sobel R.A., Mitchell M.E. Fibronectin in multiple sclerosis lesions. Am. J. Pathol. 1989, 135:161-168.
27. Takahashi K., Miyake S., Kondo T., Terao K., Hatakenaka M., Hashimoto S., Yamamura T. Natural killer type 2 bias in remission of multiple sclerosis. J. Clin. Invest. 2001, 107:R23-R29.
28. Takahashi K., Aranami T., Endoh M., Miyake S., Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 1:1917-1927.
29. Vandenbark A.A., Huan J., Agotsch M., La Tocha D., Goelz S., Offner H., Lanker S., Bourdette D. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 2009, 215:125-128.
30. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.